202 related articles for article (PubMed ID: 8816886)
1. Immunohistochemical detection of a fatty acid synthase (OA-519) as a predictor of progression of prostate cancer.
Shurbaji MS; Kalbfleisch JH; Thurmond TS
Hum Pathol; 1996 Sep; 27(9):917-21. PubMed ID: 8816886
[TBL] [Abstract][Full Text] [Related]
2. OA-519 (fatty acid synthase) as an independent predictor of pathologic state in adenocarcinoma of the prostate.
Epstein JI; Carmichael M; Partin AW
Urology; 1995 Jan; 45(1):81-6. PubMed ID: 7817483
[TBL] [Abstract][Full Text] [Related]
3. Increased expression of fatty acid synthase (OA-519) in ovarian neoplasms predicts shorter survival.
Gansler TS; Hardman W; Hunt DA; Schaffel S; Hennigar RA
Hum Pathol; 1997 Jun; 28(6):686-92. PubMed ID: 9191002
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of fatty acid synthase is an early and common event in the development of prostate cancer.
Swinnen JV; Roskams T; Joniau S; Van Poppel H; Oyen R; Baert L; Heyns W; Verhoeven G
Int J Cancer; 2002 Mar; 98(1):19-22. PubMed ID: 11857379
[TBL] [Abstract][Full Text] [Related]
5. Fatty acid synthesis: a potential selective target for antineoplastic therapy.
Kuhajda FP; Jenner K; Wood FD; Hennigar RA; Jacobs LB; Dick JD; Pasternack GR
Proc Natl Acad Sci U S A; 1994 Jul; 91(14):6379-83. PubMed ID: 8022791
[TBL] [Abstract][Full Text] [Related]
6. Expression of oncogenic antigen 519 (OA-519) in prostate cancer is a potential prognostic indicator.
Shurbaji MS; Kuhajda FP; Pasternack GR; Thurmond TS
Am J Clin Pathol; 1992 May; 97(5):686-91. PubMed ID: 1374214
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical detection of p53 protein as a prognostic indicator in prostate cancer.
Shurbaji MS; Kalbfleisch JH; Thurmond TS
Hum Pathol; 1995 Jan; 26(1):106-9. PubMed ID: 7821906
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical study of fatty acid synthase in ovarian neoplasms.
Alò PL; Visca P; Framarino ML; Botti C; Monaco S; Sebastiani V; Serpieri DE; Di Tondo U
Oncol Rep; 2000; 7(6):1383-8. PubMed ID: 11032949
[TBL] [Abstract][Full Text] [Related]
9. Caveolin-1 expression is a predictor of recurrence-free survival in pT2N0 prostate carcinoma diagnosed in Japanese patients.
Satoh T; Yang G; Egawa S; Addai J; Frolov A; Kuwao S; Timme TL; Baba S; Thompson TC
Cancer; 2003 Mar; 97(5):1225-33. PubMed ID: 12599229
[TBL] [Abstract][Full Text] [Related]
10. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of fatty acid synthase in prostate cancer recurrence: SUV of [(11) C]acetate PET as a prognostic marker.
Leisser A; Pruscha K; Ubl P; Wadsak W; Mayerhöfer M; Mitterhauser M; Hacker M; Kramer G; Shariat S; Karanikas G; Hartenbach M; Haug AR
Prostate; 2015 Nov; 75(15):1760-7. PubMed ID: 26282590
[TBL] [Abstract][Full Text] [Related]
12. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
[TBL] [Abstract][Full Text] [Related]
13. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2014 Sep; 15(10):1076-89. PubMed ID: 25130995
[TBL] [Abstract][Full Text] [Related]
14. The independent impact of extended pattern biopsy on prostate cancer stage migration.
Master VA; Chi T; Simko JP; Weinberg V; Carroll PR
J Urol; 2005 Nov; 174(5):1789-93; discussion 1793. PubMed ID: 16217288
[TBL] [Abstract][Full Text] [Related]
15. Do clinically insignificant tumors of the prostate exist?
Stamatiou K; Alevizos A; Mariolis A; Spiliopoulou C; Alevizou A; Bovis K; Sofras F
Urol Int; 2008; 81(4):379-82. PubMed ID: 19077395
[TBL] [Abstract][Full Text] [Related]
16. Expression of sialylated MUC1 in prostate cancer: relationship to clinical stage and prognosis.
Arai T; Fujita K; Fujime M; Irimura T
Int J Urol; 2005 Jul; 12(7):654-61. PubMed ID: 16045558
[TBL] [Abstract][Full Text] [Related]
17. A retrospective study of high mobility group protein I(Y) as progression marker for prostate cancer determined by in situ hybridization.
Tamimi Y; van der Poel HG; Karthaus HF; Debruyne FM; Schalken JA
Br J Cancer; 1996 Aug; 74(4):573-8. PubMed ID: 8761372
[TBL] [Abstract][Full Text] [Related]
18. Androgen receptor expression in prostate cancer lymph node metastases is predictive of outcome after surgery.
Sweat SD; Pacelli A; Bergstralh EJ; Slezak JM; Cheng L; Bostwick DG
J Urol; 1999 Apr; 161(4):1233-7. PubMed ID: 10081876
[TBL] [Abstract][Full Text] [Related]
19. Radical prostatectomy for impalpable prostate cancer: the Johns Hopkins experience with tumors found on transurethral resection (stages T1A and T1B) and on needle biopsy (stage T1C).
Epstein JI; Walsh PC; Brendler CB
J Urol; 1994 Nov; 152(5 Pt 2):1721-9. PubMed ID: 7523719
[TBL] [Abstract][Full Text] [Related]
20. Visual estimation of tumour extent is not an independent predictor of prostate specific antigen recurrence.
Jones TD; Koch MO; Lin H; Cheng L
BJU Int; 2005 Dec; 96(9):1253-7. PubMed ID: 16287440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
